Photobiomodulation and alopecia: a crowdsourced survey study on patient preferences.
Autor: | Paiewonsky B; University of Minnesota Department of Dermatology, Minneapolis, MN, USA.; Medical, Charles E. Schmidt College of Medicine at Florida Atlantic University, Boca Raton, FL, USA., Winter M; University of Minnesota Department of Dermatology, Minneapolis, MN, USA.; Midwestern University Chicago College of Osteopathic Medicine, Downers Grove, IL, USA., Hordinsky M; University of Minnesota Department of Dermatology, Minneapolis, MN, USA., Griffith M; University of Minnesota Department of Dermatology, Minneapolis, MN, USA.; Rush Medical College, Chicago, IL, USA., Farah RS; University of Minnesota Department of Dermatology, Minneapolis, MN, USA. |
---|---|
Jazyk: | angličtina |
Zdroj: | Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology [J Cosmet Laser Ther] 2023 Nov 17; Vol. 25 (5-8), pp. 92-94. Date of Electronic Publication: 2023 Nov 27. |
DOI: | 10.1080/14764172.2023.2284641 |
Abstrakt: | Photobiomodulation is a treatment option for hair loss and is currently FDA cleared for androgenetic alopecia. There are a variety of photobiomodulation devices intended for at-home patient use. However, data examining user preferences is lacking. A social media-based, online survey study was completed to understand patient preferences when selecting a photobiomodulation device. Secondary outcomes examined patient experience with the device. Sixty participants responded to the 21-question survey. The majority of participants had never used a photobiomodulation device ( n = 50; 86.2%). Most respondents ( n = 40; 67.8%) felt the efficacy of the device was the most important aspect to consider when selecting a photobiomodulation device. Additionally, a majority of participants thought 15 ( n = 22; 37.3%) or 20 minutes ( n = 17; 28.8%) would be a reasonable treatment duration and would prefer a hand-free device ( n = 51; 86.4%). Of the eight participants who had used a photobiomodulation device, only one was dissatisfied with the device and discontinued treatment. |
Databáze: | MEDLINE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |